Vitrolife AB (publ): Interim Report January-September 2014: Good Growth and Considerably Stronger Results

Regulatory News:

Vitrolife AB (publ) (STO:VITR) :

Third quarter:

· Sales growth was 9 percent in local currency. Sales amounted to SEK 125 (109) million, corresponding to an increase of 15 percent in SEK. Last year’s figure included sales of the transplantation product STEEN Solution™ to Xvivo to the tune of SEK 3 million. Adjusted for this, the increase in sales amounted to 12 percent in local currency.

· Operating income (EBIT) amounted to SEK 44 (23) million, corresponding to an operating margin of 35 (21) percent.

· Net income amounted to SEK 36 (17) million, which gave earnings per share of SEK 1.79 (0.85).

January - September:

· Sales growth was 10 percent in local currency. Sales amounted to SEK 374 (329) million, corresponding to an increase of 13 percent in SEK. Last year’s figure included sales of the transplantation product STEEN Solution™ to Xvivo to the tune of SEK 8 million. Adjusted for this, the increase in sales amounted to 12 percent in local currency.

· Operating income (EBIT) amounted to SEK 107 (59) million, corresponding to an operating margin of 29 (18) percent.

· Net income amounted to SEK 81 (41) million, which gave earnings per share of SEK 4.07 (2.06).

After the end of the period:

· Vitrolife AB has entered into an agreement to acquire all the shares of Unisense FertiliTech A/S, the market leader within the field of embryo monitoring, time-lapse, for IVF.

Gothenburg, November 6, 2014

VITROLIFE AB (publ)

Thomas Axelsson, CEO

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 6, 2014 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/) product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 250 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on NASDAQ OMX Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE13469), Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

This information was brought to you by Cision http://news.cision.com